Setting The setting was a hospital. The economic study was carried out in Besancon University hospital, France.
|
|
- Easter Helen Reynolds
- 5 years ago
- Views:
Transcription
1 Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit Tissot E, Woronoff-Lemsi M C, Cornette C, Plesiat P, Jacquet M, Capellier G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of urinary dipsticks (UDs; Multistix 8-SG) to screen asymptomatic catheterised patients for catheter-associated urinary tract infections (UTIs). Four combinations of the leukocyte (L) test pad and the nitrite (N) test pad were calculated. These were L and N, L or N, L alone and N alone. The UDs were analysed by reflectance spectrophotometry (Clinitek 50) The comparator was quantitative urine culture (QUC). Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population consisted of all consecutive asymptomatic hospitalised patients in a 15-bed medical intensive care unit. This was in addition to catheterised patients without symptoms of UTI (fever of greater than 38 degrees C, dysuria or suprapubic tenderness). The physicians decided on the lack of symptoms. Patients without urinary catheterisation, or with symptoms of catheter-associated UTI at the time of sampling, were excluded. Setting The setting was a hospital. The economic study was carried out in Besancon University hospital, France. Dates to which data relate The effectiveness and cost data were collected between 1 March and 31 August The price year was Source of effectiveness data The effectiveness data were derived from a single study. Link between effectiveness and cost data The resource data were taken from the same patient sample as the effectiveness data. The data were collected prospectively. Study sample The sample comprised all consecutive, asymptomatic catheterised patients at the hospital. The ratio of males to females was 1.9 and the average age of the sample was 56 years. No power calculations to determine the sample size were reported. The study sample was appropriate for the clinical study question, as the patients were catheterised and the Page: 1 / 5
2 most frequently isolated uropathogens have no nitrate reductase activity. A total of 339 urine samples from 144 patients were analysed. Subsequently, 22 patients were excluded from the study because they were not catheterised (17) or had symptoms of catheter-associated UTI (5). The mean number of samples taken per patient was 2.6. Study design This was a prospective cohort study carried out in a single centre. On patient admission, and thereafter once a week, a QUC and a UD were performed on the same urine sample. The length of follow-up was 6 months. Analysis of effectiveness The clinical study was analysed on an intention to treat basis. The health outcome used in the analysis was the number of asymptomatic catheter-associated UTIs. The performance of the different screening methods was assessed using the specificity, sensitivity, positive predictive value and negative predictive value. Since the strategies were performed on the same sample, issues concerning comparability, confounding and selection bias were minimised. The paper provided baseline characteristics of the patients. Effectiveness results The performance decreased with the positive level of QUC for all combinations. The incidence of asymptomatic catheter-associated UTIs was 31.1% (at least 10^5 organisms/ml). The effectiveness (sensitivity) was 1 for QUC and for UDs (L or N combination). In the UD strategy, the L or N combination was the better combination with which to screen catheterised patients for catheter-associated UTIs. The sensitivity was 87.2% (95% confidence interval, CI: ), the specificity was 61.6%, the positive predictive value was 30.6%, and the negative predictive value was 96.1% (95% CI: ). A total of 157 (46.3%) UDs were positive for L or N combination. Only 7 false-negative results were observed with this combination. All false-negative results were observed with patients with haematuria and 86% (6 out of 7) of the patients with proteinuria. The performance of the leukocyte test pad alone was nearly equal to the performance of the L or N combination. Clinical conclusions The authors concluded that UDs are an effective rapid test for screening for asymptomatic, catheter-associated UTIs in intensive care unit patients. Measure of benefits used in the economic analysis The outcome measure used for the economic analysis was the performance of the screening tests in terms of the number of catheter-associated UTIs detected by each strategy. Direct costs Discounting was not carried out, which was appropriate since the costs were incurred in less than 2 years. The quantities and the costs were analysed separately. The human resource costs (nurses) were calculated for both screening methods. The QUC costs were derived from the costs of microscopic examination and culture, with or without antibiotic sensitivity. The cost data were obtained from the hospital's 1998 accountancy records. The costs of the UD strategy were for the dipsticks (Multi 8 SG) and the automated Clinitek 50. The unit cost of using automation was calculated, allowing for 5-years' depreciation. The quantities and costs were estimated using actual data. The quantities were measured in 1998 and the price year was also Statistical analysis of costs Page: 2 / 5
3 All continuous variables were presented as the mean values, along with the 95% CIs. Indirect Costs No indirect costs were measured, as the study was based on a provider perspective. Currency The currency was French francs (Ffr). These were converted into Euros (EUR) using a conversion rate of 1 EUR = Ffr Sensitivity analysis One-way sensitivity analyses were carried out to determine the degree to which the uncertainty of different parameters could influence the cost-effectiveness results. A univariate sensitivity analysis was used to analyse parameters such as the unit costs of QUC (varied by +/- 50%; EUR ), the percentage of positive dipsticks ( ), and the sensitivity of L or N combinations ( ). A multivariate analysis was also carried out on the incremental costeffectiveness ratio (ICER) under preservative conditions. These were a unit cost of EUR 10.7 for QUC, 0.7% positive dipsticks, and a sensitivity of 0.6 for the L or N combination. Estimated benefits used in the economic analysis The number of cases detected by each strategy was not explicitly reported (see the 'Synthesis of Costs and Benefits' section). Cost results The total cost of the QUC was EUR 21.5 per test. The total cost of the UD was EUR Synthesis of costs and benefits The ICER of QUC was EUR 69.5 per case of detected asymptomatic, catheter-associated UTI. The results of the oneway sensitivity analysis were sensitive to the three parameters under study. When the sensitivity of the L or N combination was 0.789, as observed with a positive level of QUC of at least 10^4 organisms/ml, the ICER of QUC was EUR 39.8 per case of detected asymptomatic, catheter-associated UTI. Under preservative conditions QUC was dominant, being more efficacious and cost-saving than UDs. The ICER was EUR -0.5 per case of detected asymptomatic, catheter-associated UTI. Authors' conclusions Although the quantitative urine culture (QUC) strategy was more effective and more costly, the authors concluded that the urinary dipstick (UD) was a rapid and cost-effective test with which to screen asymptomatic catheterised patients for QUC in a medical intensive care unit. The UD strategy decreased the cost of nosocomial infection diagnosis and the daily workload in the microbiology laboratory. CRD COMMENTARY - Selection of comparators The comparator was explicitly stated and justified (in effect the 'gold' standard test). You should decide whether this is a widely used test in your own setting. Validity of estimate of measure of effectiveness The study design appears to have been appropriate for the study question. Since both testing methods were performed Page: 3 / 5
4 on the same group of patients, there was no need to randomise and no possibility of bias due to confounding. The study population appears to have been representative of those who would need catheterisation. The authors made an assumption that the sensitivity of QUC was 100%, as it was their reference strategy. However, there is no reason to doubt this assumption. The effectiveness results should have high validity. Validity of estimate of measure of benefit The benefit measure was derived from the effectiveness results, although the number of catheter-associated UTIs detected by each strategy was not explicitly stated. Validity of estimate of costs The perspective from which the study was conducted was stated, and all the relevant costs appear to have been included. The price year was reported, and the resource quantities and the unit costs were reported separately. The unit costs and prices were generalisable to other settings, especially in Europe, as the costs were converted to a unit of currency used in these countries. Other issues The authors highlighted a limitation of their study in that the results observed did not apply to symptomatic, catheterassociated UTI. The analysis included catheterised patients without symptoms of UTI. The authors compared their findings with those of other studies. Implications of the study The authors recommend that UDs can be used at the bedside with reflectance spectrophotometric analysis. Decisionmakers should be aware that the intervention of interest was less effective than the reference strategy (QUC). The costs and outcomes of false positive and negative results associated with UDs would need to be considered if a more inclusive cost-effectiveness analysis is to be provided. Source of funding None stated. Bibliographic details Tissot E, Woronoff-Lemsi M C, Cornette C, Plesiat P, Jacquet M, Capellier G. Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit. Intensive Care Medicine 2001; 27(12): PubMedID DOI /s Indexing Status Subject indexing assigned by NLM MeSH Cost-Benefit Analysis; Cross Infection /etiology /prevention & control /urine; Female; France; Humans; Intensive Care Units /economics; Male; Mass Screening /economics; Middle Aged; Prospective Studies; Reagent Strips /economics; Sensitivity and Specificity; Urinary Catheterization /adverse effects; Urinary Tract Infections /etiology /prevention & control /urine Page: 4 / 5
5 Powered by TCPDF ( AccessionNumber Date bibliographic record published 30/06/2003 Date abstract record published 30/06/2003 Page: 5 / 5
Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis; cost-benefit analysis.
Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control Macartney K K, Gorelick M H, Manning M L, Hodinka R L, Bell L M Record Status This is a critical
More informationSetting The practice setting was secondary care. The economic study was carried out in Athens, Greece
Comparison of success rates and financial cost of extracorporeal shock-wave lithotripsy in situ and after manipulation for proximal ureteral stones Varkarakis J, Protogerou V, Albanis S, Sofras F, Deliveliotis
More informationClinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing Barenfanger J, Drake C, Kacich G
Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing Barenfanger J, Drake C, Kacich G Record Status This is a critical abstract of an economic evaluation
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Laparoscopic vs open nephrectomy in 210 consecutive patients: outcomes, cost, and changes in practice patterns Kercher K W, Heniford B T, Matthews B D, Smith T I, Lincourt A E, Hayes D H, Eskind L B, Irby
More informationTiming of prophylactic surgery in prevention of diverticulitis recurrence: a costeffectiveness
Timing of prophylactic surgery in prevention of diverticulitis recurrence: a costeffectiveness analysis Richards R J, Hammitt J K Record Status This is a critical abstract of an economic evaluation that
More informationEconomic evaluation of Helicobacter pylori eradication for peptic ulcer disease in comparison with a conventional strategy in Japan Ohara S
Economic evaluation of Helicobacter pylori eradication for peptic ulcer disease in comparison with a conventional strategy in Japan Ohara S Record Status This is a critical abstract of an economic evaluation
More informationA cost-benefit analysis of RSV prophylaxis in high-risk infants Schrand L M, Elliott J M, Ross M B, Bell E F, Mutnick A H
A cost-benefit analysis of RSV prophylaxis in high-risk infants Schrand L M, Elliott J M, Ross M B, Bell E F, Mutnick A H Record Status This is a critical abstract of an economic evaluation that meets
More informationLink between effectiveness and cost data The costing was undertaken on the same sample as that used in the effectiveness study.
Safety and efficacy of hydrogen peroxide plasma sterilization for repeated use of electrophysiology catheters Bathina M N, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto F M Record Status This
More informationHealth technology A new technique for sterilising nonlumen electrophysiology catheters that uses hydrogen peroxide gas plasma was examined.
Safety and efficacy of hydrogen peroxide plasma sterilization for repeated use of electrophysiology catheters Bathina M N, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto F M Record Status This
More informationLink between effectiveness and cost data The costing was undertaken on the same sample as that used in the effectiveness study.
Safety and efficacy of hydrogen peroxide plasma sterilization for repeated use of electrophysiology catheters Bathina M N, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto F M Record Status This
More informationCost perspectives of laparoscopic and open appendectomy Moore D E, Speroff T, Grogan E, Poulose B, Holzman M D
Cost perspectives of laparoscopic and open appendectomy Moore D E, Speroff T, Grogan E, Poulose B, Holzman M D Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationA quality improvement project comparing two regimens of medication for colonoscopy preparation Allaire J, Thompson W O, Cash B D, Galt D J
A quality improvement project comparing two regimens of medication for colonoscopy preparation Allaire J, Thompson W O, Cash B D, Galt D J Record Status This is a critical abstract of an economic evaluation
More informationCost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis Bose U, Ladkani D, Burrell A, Sharief M
Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis Bose U, Ladkani D, Burrell A, Sharief M Record Status This is a critical abstract of an economic
More informationType of intervention Primary prevention. Economic study type Cost-effectiveness analysis.
Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty Nerurkar J, Wade W E, Martin B C Record Status This is a critical abstract
More informationSetting The setting was primary care. The economic study was carried out in Northamptonshire, UK.
A cost-effectiveness analysis of domestic radon remediation in four primary care trusts located in Northamptonshire, UK Coskeran T, Denman A, Phillips P, Tornberg R Record Status This is a critical abstract
More informationSetting The setting was a hospital. The economic analysis was performed in China.
The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial Zhou Y-P, Jiang Z-M, Sun Y-H, Wang X-R, Ma
More informationLong term treatment of multiple sclerosis with interferon-beta may be cost effective Kendrick M, Johnson K I
Long term treatment of multiple sclerosis with interferon-beta may be cost effective Kendrick M, Johnson K I Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationStudy population The study population comprised fresh clinical isolates and stock cultures of clinical isolates.
Application of the Sherlock Mycobacteria Identification System using high-performance liquid chromatography in a clinical laboratory Kellogg J A, Bankert D A, Withers G S, Sweimler W, Kiehn T E, Pfyffer
More informationA cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants Oelberg D, Reininger M, Van Eeckhout J
A cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants Oelberg D, Reininger M, Van Eeckhout J Record Status This is a critical abstract of an economic
More informationTreatments for newly diagnosed multiple myeloma: analysis of survival data and costeffectiveness
Treatments for newly diagnosed multiple myeloma: analysis of survival data and costeffectiveness evaluation Trippoli S, Messori A, Becagli P, Alterini R, Tendi E Record Status This is a critical abstract
More informationSetting The setting was secondary care. The economic study was carried out in the Netherlands.
Contrast-enhanced MR angiography and digital subtraction angiography in living renal donors: diagnostic agreement, impact on decision making, and costs Kock M C, Ijzermans J N, Visser K, Hussain S M, Weimar
More informationSource of effectiveness data The evidence for effectiveness was based on a synthesis of previously completed studies.
Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Lloyd A, Aitken J A, Hoffmeyer U K, Kelso E J, Wakerly
More informationStudy population The study population comprised patients undergoing major hip or knee surgery.
Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients Dranitsaris G, Kahn S R, Stumpo C, Paton T W, Martineau J, Smith R,
More informationSetting The study setting was secondary care. The economic study was carried out in the USA.
Stereotactic breast biopsy of noncalcified lesions: a cost-minimization analysis comparing 14-gauge multipass automated core biopsy to 14- and 11-gauge vacuum-assisted biopsy Soo M S, Kliewer M A, Ghate
More informationType of intervention Secondary prevention. Economic study type Cost-effectiveness analysis.
Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin Bergqvist D, Lindgren B, Matzsch T Record Status This is a critical abstract
More informationThe cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies Thung S F, Grobman W A
The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies Thung S F, Grobman W A Record Status This is a critical abstract of an economic evaluation that
More informationHealth technology Several treatments for patients with chronic hepatitis C (CHC) were examined. The treatments were:
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned
More informationStudy population Hypothetical patients with suspected internal derangement of the shoulder.
Internal derangements of the shoulder: decision tree and cost-effectiveness analysis of conventional arthrography, conventional MRI, and MR arthrography Oh C H, Schweitzer M E, Spettell C M Record Status
More informationEconomic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial Patel A B, Dhande L A, Rawat M S
Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial Patel A B, Dhande L A, Rawat M S Record Status This is a critical abstract of an economic
More informationProphylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making Strutton D R, Stang P E
Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making Strutton D R, Stang P E Record Status This is a critical abstract of an economic
More informationType of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.
Coagulation disorders induced by L-asparaginase: correction with and without fresh-frozen plasma Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf R E Record Status This is a critical abstract of
More informationTechnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320
Dimethyl fumarate ate for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 NICE 2018. All rights reserved. Subject to Notice
More informationUrinary tract infections (UTIs) are the second most common infections, only after respiratory tract tinfections.
Detection of fu Uropathogens by Using Chromogenic Mdi Media Farzaneh Azizmohseni, Director of Persian Type Culture Collection ((PTCC) Introduction Urinary tract infections (UTIs) are the second most common
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Medical Technologies Evaluation Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Medical Technologies Evaluation Programme Sponsor submission of evidence: Evaluation title: Sponsor: Date sections A and B submitted: Date section C submitted:
More informationCost-effectiveness and cost-utility analysis accompanying Cancer Clinical trials. NCIC CTG New Investigators Workshop
Cost-effectiveness and cost-utility analysis accompanying Cancer Clinical trials NCIC CTG New Investigators Workshop Keyue Ding, PhD. NCIC Clinical Trials Group Dept. of Public Health Sciences Queen s
More informationNICE methods of technology appraisal
NICE methods of technology appraisal Zoe Garrett Senior Technical Adviser, Centre for Health Technology Evaluation National Institute for Health and Care Excellence (NICE) Contents Function of NICE Work
More informationCrowe Critical Appraisal Tool (CCAT) User Guide
Crowe Critical Appraisal Tool (CCAT) User Guide Version 1.4 (19 November 2013) Use with the CCAT Form version 1.4 only Michael Crowe, PhD michael.crowe@my.jcu.edu.au This work is licensed under the Creative
More informationTechnology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303
Teriflunomide for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303 NICE 2018. All rights reserved. Subject to Notice of
More informationAPPENDIX 18: METHODOLOGY CHECKLIST: ECONOMIC
APPENDIX 18: METHODOLOGY CHECKLIST: ECONOMIC EVALUATIONS This checklist is designed to determine whether an economic evaluation provides evidence that is useful to inform the decision-making of the Guideline
More informationBrennand et al. Trials (2016) 17:276 DOI /s y
Brennand et al. Trials (2016) 17:276 DOI 10.1186/s13063-016-1389-y STUDY PROTOCOL Antibiotic treatment for intermittent bladder catheterisation with once daily prophylaxis (the AnTIC study): Study protocol
More informationScottish Medicines Consortium
Scottish Medicines Consortium Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF) (Revised June 2007) Part A: General guidance for completion of the NPAF Part B: Guidance for
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
Diagnostics Consultation Document s THEME: LEVEL OF EVIDENCE 1. Section Response 1. Provisional Recommendations (page 2) Biomedical, Inc., the manufacturer of the My5-FU assay, is disappointed in the draft
More informationEconomic evaluations in cancer clinical trials
What is CREST? The Centre for Health Economics Research and Evaluation (CHERE) at UTS has been contracted by Cancer Australia to establish a dedicated Cancer Research Economics Support Team (CREST) to
More informationTÁMOP /2/A/KMR
HEALTH ECONOMICS HEALTH ECONOMICS Sponsored by a Grant TÁMOP-4.1.2-08/2/A/KMR-2009-0041 Course Material Developed by Department of Economics, Faculty of Social Sciences, Eötvös Loránd University Budapest
More informationA Bayesian Belief Network Model for Risk of Vascular Catheter-Associated Infection
A Bayesian Belief Network Model for Risk of Vascular Catheter-Associated Infection Reza Kazemi a, Ali Mosleh b and Meghan Dierks c a University of Maryland, College Park, currently at USFDA b University
More informationEvidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
Evidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis Produced by CRD and CHE Technology Assessment Group Authors Gill Norman, Research Fellow, CRD Stephen
More informationTeaching Vaccine Economics Everywhere Syllabus Economic Evaluation Module
Teaching Vaccine Economics Everywhere Syllabus Economic Evaluation Module The demand and cost of health services is steadily increasing due to population growth, rising income and expectations, higher
More informationMORE SAMPLES, LESS MICROSCOPE
MORE SAMPLES, LESS MICROSCOPE WE HAVE A SOLUTION TO YOUR NEEDS IN URINALYSIS IRIS: MOVING URINALYSIS FORWARD WE HAVE A SOLUTION TO YOUR NEEDS We can help solve your problems 1. Improved Workflow and Productivity
More informationDublin Academic Medical Centre Summer School 2009
Health Care Economics Dublin Academic Medical Centre Summer School 2009 Peter Carney UCD Geary Institute UCD School of Economics UCD Geary Institute University College Dublin Belfield, Dublin 4 Ireland
More informationargatroban, 100mg/ml, concentrate for solution for infusion (Exembol) SMC No. (812/12) Mitsubishi Pharma Europe Ltd
argatroban, 100mg/ml, concentrate for solution for infusion (Exembol) SMC No. (812/12) Mitsubishi Pharma Europe Ltd 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationEconomic evaluation of Telaprevir (Incivo ) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with
Economic evaluation of Telaprevir (Incivo ) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. January 2012 Telaprevir Summary 1.
More informationReport on Guidelines for Health economic analyses of medicinal products
Anita Alban Hans Keiding Jes Søgaard March 1998 Report on Guidelines for Health economic analyses of medicinal products In 1997, the Danish Ministry of Health set up a working group consisting of: Research
More informationScottish Medicines Consortium
Scottish Medicines Consortium interferon alfa 2b (Viraferon and Intron A* ) 18 million IU, solution for injection, multidose pen in combination with ribavirin (Rebetol ) capsules 200 mg No. (258/06) Schering
More informationTechnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta407
Secukinumab for active ankylosing spondylitis after treatment with non- steroidal anti-inflammatory drugs or TNF-alpha inhibitors Technology appraisal guidance Published: 28 September 16 nice.org.uk/guidance/ta407
More informationTrial-design in biosimilar research: Equivalence or non-inferiority design
Trial-design in biosimilar research: Equivalence or non-inferiority design Prof. Kit C.B. Roes Professor of Clinical Trial Methodology Advisor to MEB-CBG Overview The place(s) of the clinical efficacy
More informationWorkshop on flexible designs for diagnostic studies. from diagnostic accuracy to personalized medicine
Workshop on flexible designs for diagnostic studies from diagnostic accuracy to personalized medicine Structure Background Sources of error Summary 06/11/2017 Introduction 2 Structure Background Sources
More informationTrue Walkaway Automated Urinalysis, Chemistry to Microscopy The CLINITEK AUWi System Answers for life.
www.siemens.com/diagnostics True Walkaway Automated Urinalysis, Chemistry to Microscopy The CLINITEK AUWi System Answers for life. Can I achieve true unattended urinalysis testing in my laboratory? With
More informationSmartphone-Based Urine Reagent Strip Test in the Emergency Department
Smartphone-Based Urine Reagent Strip Test in the Emergency Department Karam Choi, BS, 1, * Ikwan Chang, MD, 2, * Jung Chan Lee, PhD, 3 5 Do Kyun Kim, MD, PhD, 2 Seungwoo Noh, PhD, 1 Heejeong Ahn, EMT,
More informationFormalizing Study Design & Writing Your Protocol. Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care
TWIST: Formalizing Study Design & Writing Your Protocol Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care Presented by the Joint Clinical Trials Office/Quality Assurance Unit
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
More informationDraft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September
23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis
More informationNoncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant.
Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant tuberculosis Policy statement March 2010 1 Contents Abbreviations Executive summary 1.
More informationApplying pharmacoeconomics to everyday clinical practice
Applying pharmacoeconomics to everyday clinical practice Brought to you by Pfizer Limited Date of preparation: August 2016; Job code: PP-GEP-GBR-0083 1 Objectives To provide healthcare professionals (HCPs)
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)
Public slides part 1 (Redacted) Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) 3 rd Appraisal Committee meeting Committee B, 16 th November 2017 Previous Appraisal
More informationPharmacovigilance & Signal Detection
Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,
More informationHow To Design A Clinical Trial. Statistical Analysis. Gynecologic Cancer InterGroup
How To Design A Clinical Trial Statistical Analysis Andrew Embleton PhD student/medical Statistician MRC Clinical Trials Unit at UCL At what points do you need to consider statistics? At what points do
More informationThe challenges of preparing evidence for decision modelling. Marta Soares Centre for Health Economics, University of York
The challenges of preparing evidence for decision modelling Marta Soares Centre for Health Economics, University of York MRC biostats 10/02/2015 Overview Context Overview of decision modelling Overview
More informationLassa fever A neglected disease in Africa Who are the patients and what are their outcomes?
Lassa fever A neglected disease in Africa Who are the patients and what are their outcomes? A Dahmane, R Zachariah, R Van den Bergh, T Reid, Y Nzomukunda, M Allaouna,P Alders,M Van Herp,R Souya, Dr Grant,
More informationUSE OF PRIMARY CARE DATABASES IN EPIDEMIOLOGIC RESEARCH
USE OF PRIMARY CARE DATABASES IN EPIDEMIOLOGIC RESEARCH Luis Alberto García Rodríguez Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain Index The structure to successfully perform
More informationSponsor- vs. investigator-initiated clinical intervention research. Jan P Vandenbroucke Leiden University Medical Center
Sponsor- vs. investigator-initiated clinical intervention research Jan P Vandenbroucke Leiden University Medical Center Outline The problem with industry-sponsored research The problem with investigator-initiated
More informationSchool of Social and Community Medicine
PLEASE DO NOT REPRODUCE Data, Models, and Research: The Role of VoI Methods in Arthritis Nicky J Welton Biologic Therapies in Inflammatory Joint Diseases: Models for Decision Making Arthritis Research
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationField trial with veterinary vaccine
١ Field trial with veterinary vaccine Saeedeh Forghani,, M.D. Clinical Trial and Ethics Department Human Health Management Deputy of Quality Assurance 89/4/2 ٢ ٣ Introduction: The efficacy and safety shall
More informationCOMBACTE-NET. Update on ANTICIPATE Study Vienna, Austria MARIA J.G.T. VEHRESCHILD UNIVERSITY HOSPITAL COLOGNE, GERMANY
COMBACTE-NET Update on ANTICIPATE Study Vienna, Austria MARIA J.G.T. VEHRESCHILD UNIVERSITY HOSPITAL COLOGNE, GERMANY 24.04.2017 WP7 Overview ANTICIPATE clinical study: AssessmeNT of the Incidence of Clostridium
More informationAPPRAISAL OF CLINICAL TRIALS. Su May Liew CEBM Oxford
APPRAISAL OF CLINICAL TRIALS Su May Liew CEBM Oxford Good study Experimental - RCT Fit question - PICO Passes appraisal - RAMMbo Minimises random error - statistics Why a trial? It may be better to do
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux sodium, 2.5mg/0.5ml solution for injection, pre-filled syringe (Arixtra ) No. (420/07) GlaxoSmithKline 09 November 2007 The Scottish Medicines Consortium has
More informationTo provide a framework and tools for planning, doing, checking and acting upon audits
Document Name: Prepared by: Quality & Risk Unit Description Audit Process The purpose of this policy is to develop and sustain a culture of best practice in audit through the use of a common framework
More informationValue Assessment: Building Payercentric value propositions to inform decision-making
Value Assessment: Building Payercentric value propositions to inform decision-making Aris Angelis and Panos Kanavos Medical Technology Research Group, LSE Health Advance-HTA dissemination workshop, Santiago,
More informationNDA Requirements: Surveillance, Clinical Trial Data, Breakpoints
NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Kevin M. Krause Director Microbiology Achaogen, Inc. Presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of
More informationBoceprevir for the treatment of genotype 1 chronic hepatitis C
Boceprevir for the treatment of genotype 1 chronic Issued: April 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationEvidence Grading and Recommendations
Process Document: Existing and emerging technologies used for decontamination of the healthcare environment Evidence Grading and Recommendations Version: 1.0 Date: July 2017 Owner/Author: Infection Control
More informationDefining the true market
Defining the true market Case study: How real-world data and outcomes improved a major pharmaceutical company s launch strategy Cardinal Health Specialty Solutions Competing in a crowded marketplace A
More informationSAMPLE. Urinalysis; Approved Guideline Third Edition
February 2009 Urinalysis; Approved Guideline Third Edition This document addresses procedures for testing urine, including materials and equipment; macroscopic/physical evaluation; chemical analysis; and
More informationAntimicrobial Surfaces to Prevent Healthcare-Associated Infection
Antimicrobial Surfaces to Prevent Healthcare-Associated Infection Matthew P. Muller, MD, PhD, FRCPC Medical Director, Infection Prevention and Control, St. Michael s Hospital Chair, Provincial Infectious
More informationPHA 5128 Case Study # 4. Enter New Patient in Patient Assessment: Select Patient / New Patient and enter all information.
1. Gertrude Thompson MR #: 190522 Account #: 15028 Admission Date: 7/18/94 Physician: Jack Long, Infectious Disease Location: 4 West, Room 408, Bed C Female Black DOB: 2/5/1956 5 4 (163 cm), 220 lbs. (99.79
More informationMLT 116L Clinical Microbiology Lab
Page 1 of 5 MLT 116L Clinical Microbiology Lab Approval Date: Effective Term: Department: MEDICAL LABORATORY TECHNICIAN Division: Allied Health/Public Safety Units: 1.00 Grading Option: Letter Grade Transferability:
More informationEvaluation & Decision Guides
SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM Evaluation & Decision Guides 2014 Revision (v3) New ideas & Improvements Department of Surgery Evidence Decision Support Program Resource
More informationThe Future of Personalised Medicine and Health
The Future of Personalised Medicine and Health Mike Messenger Head of Leeds Centre for Personalised Medicine & Health Deputy Director, NIHR Leeds In Vitro Diagnostic Co-Operative A Vision of Personalised
More informationPredictive Analytics in
Predictive Analytics in Emergency Medicine: Improving Patient Flow, Access, Experience and Profitability Timothy Reeder, MD, Vidant Medical Center Tommy Bohrmann, PhD, Roundtable Analytics Vidant Medical
More informationDynamic Bayesian Markov models for health economic evaluations of interventions in infectious disease
Dynamic Bayesian Markov models for health economic evaluations of interventions in infectious disease Katrin Haeussler Department of Statistical Science University College London Joint work with Gianluca
More informationHTA and market access issues for a complex intervention
5th HTA network meeting, Paris 29th October 2015 HTA and market access issues for a complex intervention Marianne Klemp, Research Director, Norwegian Knowledge Centre for the Health Services, NOKC Example
More informationRESEARCH DURING PUBLIC HEALTH EMERGENCIES- ETHICAL ISSUES
RESEARCH DURING PUBLIC HEALTH EMERGENCIES- ETHICAL ISSUES Prof. Suma Krishnasastry Prof of Medicine Govt. T. D. Medical College, Alappuzha, Kerala, INDIA Public health Emergency Hallmark of a Public Health
More informationThe relationship between measurement uncertainty and reporting interval
Bond University epublications@bond Faculty of Health Sciences & Medicine Publications Faculty of Health Sciences & Medicine The relationship between measurement uncertainty and reporting interval Tony
More informationClinical experience with Raxone (idebenone) in the treatment of patients with Leber s Hereditary Optic Neuropathy (LHON)
Clinical experience with Raxone (idebenone) in the treatment of patients with Leber s Hereditary Optic Neuropathy (LHON) Günther Metz, Santhera Pharmaceuticals Disclaimer 2 This presentation is not and
More informationORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon
ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT Dr Philippe CASSIER Centre Léon Bérard, Lyon Outline Cancer & Oncology Drug development in oncology Specificity of phase I trials in oncology Study design
More information1.0 Abstract. Title. Synagis liquid 50 mg, 100 mg for Intramuscular Injection: Special Investigation in Immunocompromised Children with Synagis
1.0 Abstract Title Synagis liquid 50 mg, 100 mg for Intramuscular Injection: Special Investigation in Immunocompromised Children with Synagis Keywords Palivizumab, respiratory syncytial virus, immunocompromised
More informationthe Simple, Efficient, Effective
IVD solutions through partnership R the Simple, Efficient, Effective solution for urine microbiology Technical Information R The microbiological analysis of urine samples for urinary tract infections (UTI)
More information